CLINICAL TRIALS PROFILE FOR PHENERGAN VC
✉ Email this page to a colleague
All Clinical Trials for PHENERGAN VC
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00147680 ↗ | Uterine Papillary Serous Cancer (UPSC) Trial | Completed | Queensland Centre for Gynaecological Cancer | Phase 2 | 2004-09-01 | This study will be an open, non-randomised, clinical phase 2 trial, which will involve 30 women diagnosed with uterine papillary serous cancer. The researchers will investigate the effect of four cycles of paclitaxel/carboplatin, followed by whole pelvic external beam radiotherapy to a standard pelvis field (50.4 Gy) with or without a para-aortic boost with respect to the safety and efficacy of treatment, and patterns of recurrence. |
| NCT00426491 ↗ | Misoprostol for Non-Viable Pregnancies | Completed | Madigan Army Medical Center | Phase 3 | 1999-03-01 | The purpose of this study is to examine the effectiveness of Misoprostol (Cytotec; GD Searle and Co., Chicago, IL) for the management of non-viable first trimester pregnancies. Specifically, Misoprostol (15-S-15-methyl PGE1) will be compared to a placebo with expectant management in who have documented non-viable gestations. We will examine the following outcome variables: time to resolution, number of patients requiring dilation and curettage, change in hematocrit, cost to the institution, patient satisfaction, and reported side effects. |
| NCT00541671 ↗ | Prevention of Narcotic-Induced Nausea | Terminated | Christiana Care Health Services | N/A | 2007-02-01 | We are doing this study to find out if extra medicine is needed to avoid the chance of nausea sometimes linked to narcotic pain medicine (for example, morphine, dilaudid, fentanyl). Some doctors always give medicine to prevent the possible side effect of nausea, while others do not. We are looking to see if this extra medicine is helpful in preventing nausea. The goal is to screen all patients with pain and enroll enough subjects to reach our goal of 164 evaluable study participants. |
| NCT00895531 ↗ | Combination of Peripheral Nerve Block and DepoDur in Total Knee Joint Replacement | Terminated | EKR Therapeutics, Inc | Phase 4 | 2009-12-01 | The investigators hypothesize that patients who receive a femoral catheter with low dose epidural Depodur will experience comparable or superior pain relief than those who receive both femoral and sciatic catheters. In addition, the investigators hypothesize that the one catheter will be less time consuming to place and facilitate early ambulation of the patient. |
| NCT00895531 ↗ | Combination of Peripheral Nerve Block and DepoDur in Total Knee Joint Replacement | Terminated | University of Louisville | Phase 4 | 2009-12-01 | The investigators hypothesize that patients who receive a femoral catheter with low dose epidural Depodur will experience comparable or superior pain relief than those who receive both femoral and sciatic catheters. In addition, the investigators hypothesize that the one catheter will be less time consuming to place and facilitate early ambulation of the patient. |
| NCT01118884 ↗ | Effects of Oral Midazolam in Comparison Promethazine With Nitrous Oxide for Uncooperative Children | Unknown status | Shahid Beheshti University | Phase 3 | 2009-06-01 | The purpose of this study is to compare the safety and efficacy of sedation using orally administered midazolam and promethazine with nitrous oxide/oxygen in uncooperative children receiving dental treatments. |
| NCT01510379 ↗ | Reletex Versus Standard of Care Therapy for Post-Operative Nausea Control in Patients Undergoing Foregut Surgery | Completed | Kyle A Perry | N/A | 2011-08-01 | The effect a ReletexTM device has on postoperative nausea and vomiting when used with ondansetron after foregut surgery will be studied. A ReletexTM device is a FDA approved wristwatch-like device that painlessly stimulates a nerve in the wrist and has been shown to decrease nausea and vomiting. The investigators will randomize 100 patients who are having a fundoplication for either gastroesophageal reflux disease (GERD), paraesophageal hernia, or Heller Myotomy for achalasia into two groups. A control group will receive scheduled ondansetron for prevention and treatment of postoperative nausea and vomiting and phenergan as needed. The treatment group will wear a ReletexTM wrist band after surgery for 7 days. These patients will also get scheduled ondansetron and phenergan as needed, like the control group. The investigators will compare nausea, retching, and the amount of supplemental nausea medication used between the two groups. The patients will be provided a diary to document their nausea, retching, and medication use. The hypothesis of this study is that use of the ReletexTM device will reduce post-operative nausea and vomiting, and will reduce post-operative use of anti-emetic medications in patients who have undergone foregut surgery. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for PHENERGAN VC
Condition Name
Clinical Trial Locations for PHENERGAN VC
Trials by Country
Clinical Trial Progress for PHENERGAN VC
Clinical Trial Phase
Clinical Trial Sponsors for PHENERGAN VC
Sponsor Name
